The aim of this study was to examine expression of AKR1C3 in endometrial and ovarian cancers, and possible correlations between AKR1C3 expression and clinicopathological data, along with evaluation of AKR1C3 as a prognostic biomarker of OS and a predictive biomarker for chemotherapy response. This evidence concerns the gene AKR1C3 and ovarian cancer.